Todd M Pitts

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11387659/publications.pdf

Version: 2024-02-01

54 papers	2,561 citations	257357 24 h-index	197736 49 g-index
54 all docs	54 docs citations	54 times ranked	5724 citing authors

#	Article	IF	Citations
1	Preclinical Development of the Class-Iâ€“Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. Molecular Cancer Therapeutics, 2022, 21, 397-406.	1.9	8
2	Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Frontiers in Immunology, 2021, 12, 607282.	2.2	19
3	WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 642328.	1.3	13
4	Modulating Enzyme Function via Dynamic Allostery within Biliverdin Reductase B. Frontiers in Molecular Biosciences, 2021, 8, 691208.	1.6	5
5	Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patientâ€derived xenograft tumors. Molecular Carcinogenesis, 2020, 59, 1227-1240.	1.3	6
6	RX-5902, a novel Î²-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer. BMC Cancer, 2020, 20, 1063.	1.1	16
7	Structure, dynamics and function of the evolutionarily changing biliverdin reductase B family. Journal of Biochemistry, 2020, 168, 191-202.	0.9	9
8	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clinical Cancer Research, 2020, 26, 4633-4642.	3.2	7
9	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 1598-1612.	1.9	19
10	Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. Cancers, 2020, 12, 719.	1.7	15
11	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits Î²-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 1916-1925.	1.9	21
12	Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clinical Cancer Research, 2019, 25, 3352-3365.	3.2	18
13	Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. Endocrine-Related Cancer, 2019, 26, 765-778.	1.6	15
14	Development of new preclinical models to advance adrenocortical carcinoma research. Endocrine-Related Cancer, 2018, 25, 437-451.	1.6	45
15	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer, 2018, 18, 136.	1.1	13
16	ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Molecular Cancer Therapeutics, 2018, 17, 222-231.	1.9	38
17	Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. Anti-Cancer Drugs, 2018, 29, 827-838.	0.7	9
18	Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clinical Cancer Drugs, 2018, 5, 42-49.	0.3	4

#	Article	IF	Citations
19	A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Oncologist, 2018, 23, 1409-e140.	1.9	7
20	Biliverdin Reductase B Dynamics Are Coupled to Coenzyme Binding. Journal of Molecular Biology, 2018, 430, 3234-3250.	2.0	22
21	A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Research, 2018, 20, 82.	2.2	44
22	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Research, 2018, 78, 5398-5407.	0.4	20
23	Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Molecular Cancer Therapeutics, 2018, 17, 2112-2122.	1.9	33
24	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). Investigational New Drugs, 2017, 35, 11-25.	1.2	15
25	Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Frontiers in Oncology, 2017, 7, 94.	1.3	19
26	The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. Oncotarget, 2017, 8, 110904-110913.	0.8	18
27	HDAC and PD-1 inhibition in humanized triple-negative breast cancer xenografts.. Journal of Clinical Oncology, 2017, 35, e14604-e14604.	0.8	0
28	Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate. Journal of the American Association for Laboratory Animal Science, 2017, 56, 166-172.	0.6	9
29	Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. Journal of Visualized Experiments, 2016, , .	0.2	15
30	Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Investigational New Drugs, 2016, 34, 176-183.	1.2	15
31	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget, 2016, 7, 50290-50301.	0.8	27
32	The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget, 2016, 7, 28273-28285.	0.8	34
33	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC Genomics, 2015, 16, S2.	1.2	12
34	Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Frontiers in Pharmacology, 2015, 6, 120.	1.6	21
35	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 1117-1129.	1.9	32
36	Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants. Molecular Cancer Therapeutics, 2015, 14, 317-325.	1.9	43

#	Article	IF	Citations
37	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget, 2015, 6, 34561-34572.	0.8	10
38	Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer. PLoS ONE, 2014, 9, e113037.	1.1	40
39	Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. , 2014, 142, 258-269.		75
40	Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2013, 19, 4149-4162.	3.2	61
41	Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models. Clinical Cancer Research, 2013, 19, 291-303.	3.2	40
42	Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models. Clinical Cancer Research, 2013, 19, 6219-6229.	3.2	53
43	Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Frontiers in Pharmacology, 2013, 4, 22.	1.6	30
44	Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in Pharmacology, 2013, 4, 35.	1.6	32
45	Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. Clinical Cancer Research, 2012, 18, 1051-1062.	3.2	41
46	Common PIK3CA Mutants and a Novel 3â€² UTR Mutation Are Associated with Increased Sensitivity to Saracatinib. Clinical Cancer Research, 2012, 18, 2704-2714.	3.2	41
47	Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews Clinical Oncology, 2012, 9, 338-350.	12.5	1,091
48	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 849-860.	3.2	58
49	Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-rasâ€“Mutated Colorectal Cancer. Molecular Cancer Therapeutics, 2010, 9, 3351-3362.	1.9	71
50	Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development. Clinical Cancer Research, 2010, 16, 3193-3204.	3.2	70
51	The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models. Clinical Cancer Research, 2010, 16, 5436-5446.	3.2	38
52	Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Lineâ€“Derived Human Colorectal Cancer Xenograft Models. Clinical Cancer Research, 2010, 16, 2989-2998.	3.2	42
53	Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Molecular Cancer Therapeutics, 2009, 8, 2546-2558.	1.9	40
54	Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Molecular Cancer Therapeutics, 2009, 8, 342-349.	1.9	62